問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Taipei Veterans General Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • 112Taipei CityBeitou

Recruiting Trial

900Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

2245Cases

2017-04-01 - 2018-12-31

Phase III

A PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLINDED ENDPOINT EVALUATION (PROBE) PARALLEL GROUP STUDY COMPARING EDOXABAN VS. VKA IN SUBJECTS UNDERGOING CATHETER ABLATION OF NON-VALVULAR ATRIAL FIBRILLATION (ELIMINATE-AF)

  • Condition/Disease

    Non-valvular atrial fibrillation (AF)

  • Test Drug

    Edoxaban (DU-176b)

Participate Sites
6Sites

Terminated5Sites

2017-01-05 - 2019-12-31

Others

An Open-Label, Multicenter Phase Ib Study of The Safety and Efficacy of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab and/or Other Treatments in Patients With Solid Tumors

  • Condition/Disease

    Solid Tumors

  • Test Drug

    TECENTRIQ

Participate Sites
6Sites

Recruiting4Sites

Terminated1Sites

趙毅
Taipei Veterans General Hospital

陳仁熙
Linkou Chang Gung Medical Foundation

2017-04-15 - 2018-08-27

Phase I

A RANDOMIZED, SPONSOR-OPEN, INVESTIGATOR-BLINDED, SUBJECT-BLINDED, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7049389 IN: (1) SINGLE- (WITH OR WITHOUT FOOD) AND MULTIPLE- (WITH MIDAZOLAM) ASCENDING DOSES IN HEALTHY VOLUNTEERS; (2) PATIENTS CHRONICALLY INFECTED WITH HEPATITIS B VIRUS

  • Condition/Disease

    HEPATITIS B VIRUS

  • Test Drug

    RO7049389

Participate Sites
7Sites

Recruiting6Sites

葉昭廷
Linkou Chang Gung Medical Foundation

2017-10-16 - 2019-05-31

Phase I

A RANDOMIZED, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOKINETICS AND PHARMACODYNAMICS OF SUBCUTANEOUS ADMINISTRATION OF RO7062931 WITH SINGLE ASCENDING DOSES IN HEALTHY VOLUNTEERS AND MULTIPLE DOSES AND MODIFIED REGIMENS IN VIROLOGICALLY SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION

  • Condition/Disease

    CHRONIC HEPATITIS B VIRUS INFECTION

  • Test Drug

    RO7062931 sterile liquid for inection

Participate Sites
5Sites

Terminated4Sites

2018-07-24 - 2021-03-17

Phase III

A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients 55 Years or Older With Type 2 Diabetes Mellitus and Inadequate Glycemic Control

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    Sotagliflozin

Participate Sites
8Sites

Terminated8Sites

江晨恩
Taipei Veterans General Hospital

2017-11-15 - 2022-12-31

Phase III

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function

  • Condition/Disease

    Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function

  • Test Drug

    Sotagliflozin

Participate Sites
10Sites

Not yet recruiting1Sites

Terminated7Sites

江晨恩
Taipei Veterans General Hospital

Division of Cardiovascular Diseases

謝宜璋
Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

2015-11-01 - 2019-12-31

Phase III

A double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    Bexagliflozin Tablets

Participate Sites
9Sites

Terminated7Sites

江晨恩
Taipei Veterans General Hospital

賴文德
Kaohsiung Municipal Gangshan Hospital

未分科

2015-10-01 - 2019-05-15

Phase III

An international, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures

  • Condition/Disease

    Symptomatic peripheral artery disease

  • Test Drug

    Xarelto tablet

Participate Sites
8Sites

Terminated7Sites

林宗憲
Kaohsiung Municipal Gangshan Hospital

未分科

江晨恩
Taipei Veterans General Hospital

2015-08-01 - 2018-12-31

Phase II

Antihypertensive effect of different doses of Rostafuroxin in comparison with Losartan, assessed by office and ambulatory blood pressure monitoring in a hypertensive population selected according to a specific genetic profile.

  • Condition/Disease

    hypertension

  • Test Drug

    Rostafuroxin

Participate Sites
14Sites

Terminated12Sites

2014-02-28 - 2017-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

1 145 146 147 148 149 225
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB